SB 1452: Uniform Controlled Substances Act; Federal Controlled Substances Act
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-04-23
Current Status:
In Progress
(2025-05-29: Act 107, on 05/29/2025 (Gov. Msg. No. 1207).)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Final Decking
Enacted
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. (CD1)
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/3000. (HD2)
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/3000. (HD1)
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/2077. (SD1)
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS.
|
THE SENATE |
S.B. NO. |
1452 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
H.D. 2 |
|
|
|
C.D. 1 |
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:
1. By amending subsection (b) to read:
"(b) [Any] Opiates. Unless specifically excepted or unless listed
in another schedule, any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers, [unless
specifically excepted,] whenever the existence of these isomers, esters,
ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
(6) Allylprodine;
(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(8) Alphameprodine;
(9) Alphamethadol;
(10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(10)] (11) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
[(11)] (12) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(12)] (13) Benzethidine;
[(13)] (14) Benzylfentanyl
(N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and
salts of isomers;
[(14)] (15) Betacetylmethadol;
[(15)] (16) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
[(16)] (17) Beta-hydroxy-3-methylfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
[(17)] (18) Beta-hydroxythiofentanyl
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
[(18)] (19) Betameprodine;
[(19)] (20) Betamethadol;
[(20)] (21) Beta-methyl fentanyl
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);
[(21)] (22) Beta'-phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl
fentanyl);
[(22)] (23) Betaprodine;
(24) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
(25) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
[(23)] (26) Butyryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
[(24)] (27) Clonitazene;
(28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);
(29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
[(25)] (30) Cyclopropyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
[(26)] (31) Dextromoramide;
[(27)] (32) Diampromide;
[(28)] (33) Diethylthiambutene;
[(29)] (34) Difenoxin;
[(30)] (35) Dimenoxadol;
[(31)] (36) Dimepheptanol;
(37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
[(32)] (38) Dimethylthiambutene;
[(33)] (39) Dioxaphetyl butyrate;
[(34)] (40) Dipipanone;
[(35)] (41) Ethylmethylthiambutene;
(42) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene);
[(36)] (43) Etonitazene;
[(37)] (44) Etoxeridine;
[(38)] (45) Fentanyl carbamate (ethyl
(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
(46) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(39)] (47) 4-fluoroisobutyryl fentanyl
[N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other
name: para-fluoroisobutyryl fentanyl);
[(40)] (48) 2'-fluoro ortho-fluorofentanyl
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other
name: 2'-fluoro 2-fluorofentanyl);
[(41)] (49) Furanyl fentanyl
(N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);
(50) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
[(42)] (51) Furethidine;
[(43)] (52) Hydroxypethidine;
(53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);
(54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
(55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(44)] (56) Ketobemidone;
[(45)] (57) Levomoramide;
[(46)] (58) Levophenacylmorphan;
(59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(47)] (61) Methoxyacetyl fentanyl
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
[(48)] (63) 4'-methyl acetyl fentanyl
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
[(49)] (64) 3-methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
[(50)] (65) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
(67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(51)] (68) Morpheridine;
[(52)] (69) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(70) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
[(53)] (71) Noracymethadol;
[(54)] (72) Norlevorphanol;
[(55)] (73) Normethadone;
[(56)] (74) Norpipanone;
(75) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (Other name: etonitazepyne);
[(57)] (76) Ocfentanil
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
[(58)] (77) Ortho-fluoroacryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
[(59)] (78) Ortho-fluorobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
[(60)] (79) Ortho-fluorofentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 2-fluorofentanyl);
(80) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
[(61)] (81) Ortho-fluoroisobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(62)] (82) Ortho-methyl acetylfentanyl
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);
[(63)] (83) Ortho-methyl methoxyacetyl fentanyl
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other
name: 2-methyl methoxyacetyl fentanyl);
(84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(64)] (85) Para-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
[(65)] (86) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide[;]);
[(66)] (87) Para-fluoro furanyl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
(89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
[(67)] (91) Para-methylfentanyl
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 4-methylfentanyl);
[(68)] (92) PEPAP
(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
[(69)] (93) Phenadoxone;
[(70)] (94) Phenampromide;
[(71)] (95) Phenomorphan;
[(72)] (96) Phenoperidine;
[(73)] (97) Phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl);
[(74)] (98) Piritramide;
[(75)] (99) Proheptazine;
[(76)] (100) Properidine;
[(77)] (101) Propiram;
(102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
[(78)] (103) Racemoramide;
(104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
[(79)] (105) Thenylfentanyl
(N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers,
salts, and salts of isomers;
[(80)] (106) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
[(81)] (107) Thiofuranyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other
names: 2-thiofuranyl fentanyl; thiophene
fentanyl);
[(82)] (108) Tilidine;
[(83)] (109) Trimeperidine; [and]
[(84)] (110) U-47700
(3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)[.];
and
(111) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)."
2. By amending subsection (d) to read:
"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine (AET);
(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
(3) 2,5-dimethoxyamphetamine (2,5-DMA);
(4) 3,4-methylenedioxy amphetamine;
(5) 3,4-methylenedioxymethamphetamine (MDMA);
(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
(11) 3,4,5-trimethoxy amphetamine;
(12) Bufotenine;
(13) 4-methoxyamphetamine (PMA);
(14) Diethyltryptamine;
(15) Dimethyltryptamine;
(16) 4-methyl-2,5-dimethoxy-amphetamine;
(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
(18) Ibogaine;
(19) Lysergic acid diethylamide;
(20) Marijuana;
(21) Parahexyl;
(22) Mescaline;
(23) Peyote;
(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Psilocybin;
(27) Psilocyn;
(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
(29) Ethylamine analog of phencyclidine (PCE);
(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
(31) Thiophene analog of phencyclidine (TPCP; TCP);
(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
(35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers;
(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
(37) Alpha-methyltryptamine (AMT);
(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(39) Salvia divinorum;
(40) Salvinorin A;
(41) Divinorin A;
(42) 5-Methoxy-N,N-Dimethyltryptamine [(5-MeO-DIPT)]
(some trade or other names:
5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);
(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
(60) 4'-chloro-alpha-pyrrolidinovalerophenone,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: 4-chloro-[alpha]-PVP;
4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
[and]
(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
(methoxetamine, MXE)[.];
(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) (Other name: bk-EBDB);
(63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation;
(64) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
(65) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11);
(66) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other name: ADB-FUBINACA);
(67) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA);
(68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: MDMB-FUBINACA); and
(69) N-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)."
3. By amending subsection (f) to read:
"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid);
[(1)] (2) Aminorex;
[(2)] (3) Cathinone;
[(3)] (4) 4,4'-dimethylaminorex (common name:
4,4'-DMAR);
(5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
[(4)] (6) Fenethylline;
(7) Mesocarb (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
[(5)] (8) Methcathinone;
(9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
[(6)] (10) 4-methylaminorex;
[(7)] (11) N-ethylamphetamine;
[(8)] (12) N,N-dimethylamphetamine;
[(9)] (13) Substituted cathinones, any compound, except
bupropion or compounds listed under a different schedule, structurally derived
from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,
naphthyl, or thiophene ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) By substitution at the 3-position with an acyclic alkyl substituent; or
(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and
[(10)] (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
(Other names:
para-methoxymethamphetamine; PMMA)."
SECTION 2. Section 329-16, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:
"(f) Immediate precursor. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
(A) Phenylacetone, phenyl-2-propanone (P2P), benzyl methyl ketone, methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine; or
(B) 1-piperidinocyclohexanecarbonitrile (PCC); or
(3) Immediate
precursor to [Fentanyl:] fentanyl:
(A) [4-anilino-N-phenethyl-4-piperidine]
4-anilino-N-phenethylpiperidine (ANPP); or
(B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)."
SECTION 3. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:
"§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.
(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Brexanolone;
(4) Bromazepam;
(5) Butorphanol;
(6) Camazepam;
(7) Carisoprodol;
(8) Chloral betaine;
(9) Chloral hydrate;
(10) Chlordiazepoxide;
(11) Clobazam;
(12) Clonazepam;
(13) Clorazepate;
(14) Clotiazepam;
(15) Cloxazolam;
(16) Daridorexant;
(17) Delorazepam;
(18) Diazepam;
(19) Dichloralphenazone (Midrin);
(20) Estazolam;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Ethyl loflazepate;
(24) Fludiazepam;
(25) Flunitrazepam;
(26) Flurazepam;
(27) Fospropofol (Lusedra);
(28) Halazepam;
(29) Haloxazolam;
(30) Ketazolam;
(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);
(32) Loprazolam;
(33) Lorazepam;
(34) Lormetazepam;
(35) Mebutamate;
(36) Medazepam;
(37) Meprobamate;
(38) Methohexital;
(39) Methylphenobarbital (mephorbarbital);
(40) Midazolam;
(41) Nimetazepam;
(42) Nitrazepam;
(43) Nordiazepam;
(44) Oxazepam;
(45) Oxazolam;
(46) Paraldehyde;
(47) Petrichloral;
(48) Phenobarbital;
(49) Pinazepam;
(50) Prazepam;
(51) Quazepam;
(52) Remimazolam;
(53) Suvorexant;
(54) Temazepam;
(55) Tetrazepam;
(56) Triazolam;
(57) Zaleplon;
(58) Zolpidem; [and]
(59) Zopiclone (Lunesta)[.]; and
(60) Zuranolone.
[(c) Fenfluramine.
Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including its salts, isomers, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible: Fenfluramine.
(d)]
(c) Stimulants. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances having a
stimulant effect on the central nervous system, including its salts, isomers,
and salts of such isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Lorcaserin;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradrol;
(12) Serdexmethylphenidate;
(13) Sibutramine;
(14) Solriamfetol; and
(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
[(e)]
(d) Other substances. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances, including its
optical isomers and its salts, isomers, and salts of isomers:
(1) Pentazocine; and
(2) Eluxadoline
(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
acid[.]).
[(f)]
(e) The department of law
enforcement may except by rule any compound, mixture, or preparation containing
any depressant substance listed in subsection (b) or any stimulant listed in
subsection [(d)] (c) from the application of all or any part of
this chapter if the compound, mixture, or preparation contains one or more
active medicinal ingredients not having a depressant or stimulant effect on the
central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the degree of
danger or probable danger of the substances which have a depressant or
stimulant effect on the central nervous system.
[(g)]
(f) Narcotic drugs. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;
(2) Dextropropoxyphene [(alpha-(+)-4-dimethylamino-1,
2-diphenyl-3-methyl-2-propionoxybutane);] (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."
SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 5. This Act shall take effect on July 1, 2025.
Report Title:
Uniform Controlled Substances Act; Federal Controlled Substances Act
Description:
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. (CD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1452 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
H.D. 2 |
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:
1. By amending subsection (b) to read:
"(b) [Any] Opiates. Unless specifically excepted or unless listed
in another schedule, any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers, [unless
specifically excepted,] whenever the existence of these isomers, esters,
ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
(6) Allylprodine;
(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(8) Alphameprodine;
(9) Alphamethadol;
(10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(10)] (11) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
[(11)] (12) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(12)] (13) Benzethidine;
[(13)] (14) Benzylfentanyl
(N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and
salts of isomers;
[(14)] (15) Betacetylmethadol;
[(15)] (16) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
[(16)] (17) Beta-hydroxy-3-methylfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
[(17)] (18) Beta-hydroxythiofentanyl
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
[(18)] (19) Betameprodine;
[(19)] (20) Betamethadol;
[(20)] (21) Beta-methyl fentanyl
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);
[(21)] (22) Beta'-phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl
fentanyl);
[(22)] (23) Betaprodine;
(24) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
(25) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
[(23)] (26) Butyryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
[(24)] (27) Clonitazene;
(28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);
(29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
[(25)] (30) Cyclopropyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
[(26)] (31) Dextromoramide;
[(27)] (32) Diampromide;
[(28)] (33) Diethylthiambutene;
[(29)] (34) Difenoxin;
[(30)] (35) Dimenoxadol;
[(31)] (36) Dimepheptanol;
(37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
[(32)] (38) Dimethylthiambutene;
[(33)] (39) Dioxaphetyl butyrate;
[(34)] (40) Dipipanone;
[(35)] (41) Ethylmethylthiambutene;
(42) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene);
[(36)] (43) Etonitazene;
[(37)] (44) Etoxeridine;
[(38)] (45) Fentanyl carbamate (ethyl
(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
(46) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(39)] (47) 4-fluoroisobutyryl fentanyl
[N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other
name: para-fluoroisobutyryl fentanyl);
[(40)] (48) 2'-fluoro ortho-fluorofentanyl
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other
name: 2'-fluoro 2-fluorofentanyl);
[(41)] (49) Furanyl fentanyl
(N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);
(50) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
[(42)] (51) Furethidine;
[(43)] (52) Hydroxypethidine;
(53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);
(54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
(55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(44)] (56) Ketobemidone;
[(45)] (57) Levomoramide;
[(46)] (58) Levophenacylmorphan;
(59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(47)] (61) Methoxyacetyl fentanyl
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
[(48)] (63) 4'-methyl acetyl fentanyl
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
[(49)] (64) 3-methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
[(50)] (65) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
(67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(51)] (68) Morpheridine;
[(52)] (69) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(70) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
[(53)] (71) Noracymethadol;
[(54)] (72) Norlevorphanol;
[(55)] (73) Normethadone;
[(56)] (74) Norpipanone;
(75) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (Other name: etonitazepyne);
[(57)] (76) Ocfentanil
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
[(58)] (77) Ortho-fluoroacryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
[(59)] (78) Ortho-fluorobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
[(60)] (79) Ortho-fluorofentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 2-fluorofentanyl);
(80) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
[(61)] (81) Ortho-fluoroisobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(62)] (82) Ortho-methyl acetylfentanyl
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);
[(63)] (83) Ortho-methyl methoxyacetyl fentanyl
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other
name: 2-methyl methoxyacetyl fentanyl);
(84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(64)] (85) Para-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
[(65)] (86) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide[;]);
[(66)] (87) Para-fluoro furanyl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
(89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
[(67)] (91) Para-methylfentanyl
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 4-methylfentanyl);
[(68)] (92) PEPAP
(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
[(69)] (93) Phenadoxone;
[(70)] (94) Phenampromide;
[(71)] (95) Phenomorphan;
[(72)] (96) Phenoperidine;
[(73)] (97) Phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl);
[(74)] (98) Piritramide;
[(75)] (99) Proheptazine;
[(76)] (100) Properidine;
[(77)] (101) Propiram;
(102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
[(78)] (103) Racemoramide;
(104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
[(79)] (105) Thenylfentanyl
(N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers,
salts, and salts of isomers;
[(80)] (106) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
[(81)] (107) Thiofuranyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other
names: 2-thiofuranyl fentanyl; thiophene
fentanyl);
[(82)] (108) Tilidine;
[(83)] (109) Trimeperidine; [and]
[(84)] (110) U-47700
(3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)[.];
and
(111) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)."
2. By amending subsection (d) to read:
"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine (AET);
(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
(3) 2,5-dimethoxyamphetamine (2,5-DMA);
(4) 3,4-methylenedioxy amphetamine;
(5) 3,4-methylenedioxymethamphetamine (MDMA);
(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
(11) 3,4,5-trimethoxy amphetamine;
(12) Bufotenine;
(13) 4-methoxyamphetamine (PMA);
(14) Diethyltryptamine;
(15) Dimethyltryptamine;
(16) 4-methyl-2,5-dimethoxy-amphetamine;
(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
(18) Ibogaine;
(19) Lysergic acid diethylamide;
(20) Marijuana;
(21) Parahexyl;
(22) Mescaline;
(23) Peyote;
(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Psilocybin;
(27) Psilocyn;
(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
(29) Ethylamine analog of phencyclidine (PCE);
(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
(31) Thiophene analog of phencyclidine (TPCP; TCP);
(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
(35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers;
(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
(37) Alpha-methyltryptamine (AMT);
(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(39) Salvia divinorum;
(40) Salvinorin A;
(41) Divinorin A;
(42) 5-Methoxy-N,N-Dimethyltryptamine [(5-MeO-DIPT)]
(some trade or other names:
5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);
(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
(60) 4'-chloro-alpha-pyrrolidinovalerophenone,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: 4-chloro-[alpha]-PVP;
4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
[and]
(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
(methoxetamine, MXE)[.];
(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) (Other name: bk-EBDB);
(63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation;
(64) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
(65) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11);
(66) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other name: ADB-FUBINACA);
(67) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA);
(68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: MDMB-FUBINACA); and
(69) N-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)."
3. By amending subsection (f) to read:
"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid);
[(1)] (2) Aminorex;
[(2)] (3) Cathinone;
[(3)] (4) 4,4'-dimethylaminorex (common name:
4,4'-DMAR);
(5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
[(4)] (6) Fenethylline;
(7) Mesocarb (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
[(5)] (8) Methcathinone;
(9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
[(6)] (10) 4-methylaminorex;
[(7)] (11) N-ethylamphetamine;
[(8)] (12) N,N-dimethylamphetamine;
[(9)] (13) Substituted cathinones, any compound, except
bupropion or compounds listed under a different schedule, structurally derived
from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,
naphthyl, or thiophene ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) By substitution at the 3-position with an acyclic alkyl substituent; or
(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and
[(10)] (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
(Other names:
para-methoxymethamphetamine; PMMA)."
SECTION 2. Section 329-16, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:
"(f) Immediate precursor. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
(A) Phenylacetone, phenyl-2-propanone (P2P), benzyl methyl ketone, methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine; or
(B) 1-piperidinocyclohexanecarbonitrile (PCC); or
(3) Immediate
precursor to [Fentanyl:] fentanyl:
(A) [4-anilino-N-phenethyl-4-piperidine]
4-anilino-N-phenethylpiperidine (ANPP); or
(B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)."
SECTION 3. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:
"§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.
(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Brexanolone;
(4) Bromazepam;
(5) Butorphanol;
(6) Camazepam;
(7) Carisoprodol;
(8) Chloral betaine;
(9) Chloral hydrate;
(10) Chlordiazepoxide;
(11) Clobazam;
(12) Clonazepam;
(13) Clorazepate;
(14) Clotiazepam;
(15) Cloxazolam;
(16) Daridorexant;
(17) Delorazepam;
(18) Diazepam;
(19) Dichloralphenazone (Midrin);
(20) Estazolam;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Ethyl loflazepate;
(24) Fludiazepam;
(25) Flunitrazepam;
(26) Flurazepam;
(27) Fospropofol (Lusedra);
(28) Halazepam;
(29) Haloxazolam;
(30) Ketazolam;
(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);
(32) Loprazolam;
(33) Lorazepam;
(34) Lormetazepam;
(35) Mebutamate;
(36) Medazepam;
(37) Meprobamate;
(38) Methohexital;
(39) Methylphenobarbital (mephorbarbital);
(40) Midazolam;
(41) Nimetazepam;
(42) Nitrazepam;
(43) Nordiazepam;
(44) Oxazepam;
(45) Oxazolam;
(46) Paraldehyde;
(47) Petrichloral;
(48) Phenobarbital;
(49) Pinazepam;
(50) Prazepam;
(51) Quazepam;
(52) Remimazolam;
(53) Suvorexant;
(54) Temazepam;
(55) Tetrazepam;
(56) Triazolam;
(57) Zaleplon;
(58) Zolpidem; [and]
(59) Zopiclone (Lunesta)[.]; and
(60) Zuranolone.
[(c) Fenfluramine.
Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including its salts, isomers, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible: Fenfluramine.
(d)]
(c) Stimulants. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances having a
stimulant effect on the central nervous system, including its salts, isomers,
and salts of such isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Lorcaserin;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradrol;
(12) Serdexmethylphenidate;
(13) Sibutramine;
(14) Solriamfetol; and
(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
[(e)]
(d) Other substances. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances, including its
optical isomers and its salts, isomers, and salts of isomers:
(1) Pentazocine; and
(2) Eluxadoline
(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
acid[.]).
[(f)]
(e) The department of law
enforcement may except by rule any compound, mixture, or preparation containing
any depressant substance listed in subsection (b) or any stimulant listed in
subsection [(d)] (c) from the application of all or any part of
this chapter if the compound, mixture, or preparation contains one or more
active medicinal ingredients not having a depressant or stimulant effect on the
central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the degree of
danger or probable danger of the substances which have a depressant or
stimulant effect on the central nervous system.
[(g)]
(f) Narcotic drugs. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;
(2) Dextropropoxyphene [(alpha-(+)-4-dimethylamino-1,
2-diphenyl-3-methyl-2-propionoxybutane);] (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."
SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 5. This Act shall take effect on July 1, 3000.
Report Title:
Uniform Controlled Substances Act; Federal Controlled Substances Act
Description:
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/3000. (HD2)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1452 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
H.D. 1 |
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:
1. By amending subsection (b) to read:
"(b) [Any] Opiates. Unless specifically excepted or unless listed
in another schedule, any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers, [unless
specifically excepted,] whenever the existence of these isomers, esters,
ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
(6) Allylprodine;
(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(8) Alphameprodine;
(9) Alphamethadol;
(10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(10)] (11) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
[(11)] (12) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(12)] (13) Benzethidine;
[(13)] (14) Benzylfentanyl
(N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and
salts of isomers;
[(14)] (15) Betacetylmethadol;
[(15)] (16) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
[(16)] (17) Beta-hydroxy-3-methylfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
[(17)] (18) Beta-hydroxythiofentanyl
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
[(18)] (19) Betameprodine;
[(19)] (20) Betamethadol;
[(20)] (21) Beta-methyl fentanyl
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);
[(21)] (22) Beta'-phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl
fentanyl);
[(22)] (23) Betaprodine;
(24) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
(25) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
[(23)] (26) Butyryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
[(24)] (27) Clonitazene;
(28) Crotonyl fentanyl ((E)-N(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide)
(29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
[(25)] (30) Cyclopropyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
[(26)] (31) Dextromoramide;
[(27)] (32) Diampromide;
[(28)] (33) Diethylthiambutene;
[(29)] (34) Difenoxin;
[(30)] (35) Dimenoxadol;
[(31)] (36) Dimepheptanol;
(37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
[(32)] (38) Dimethylthiambutene;
[(33)] (39) Dioxaphetyl butyrate;
[(34)] (40) Dipipanone;
[(35)] (41) Ethylmethylthiambutene;
(42) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene);
[(36)] (43) Etonitazene;
[(37)] (44) Etoxeridine;
[(38)] (45) Fentanyl carbamate (ethyl
(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
(46) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(39)] (47) 4-fluoroisobutyryl fentanyl
[N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other
name: para-fluoroisobutyryl fentanyl);
[(40)] (48) 2'-fluoro ortho-fluorofentanyl
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other
name: 2'-fluoro 2-fluorofentanyl);
[(41)] (49) Furanyl fentanyl
(N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);
(50) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
[(42)] (51) Furethidine;
[(43)] (52) Hydroxypethidine;
(53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);
(54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
(55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(44)] (56) Ketobemidone;
[(45)] (57) Levomoramide;
[(46)] (58) Levophenacylmorphan;
(59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(47)] (61) Methoxyacetyl fentanyl
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
[(48)] (63) 4'-methyl acetyl fentanyl
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
[(49)] (64) 3-methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
[(50)] (65) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
(67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(51)] (68) Morpheridine;
[(52)] (69) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(70) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
[(53)] (71) Noracymethadol;
[(54)] (72) Norlevorphanol;
[(55)] (73) Normethadone;
[(56)] (74) Norpipanone;
(75) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (Other name: etonitazepyne);
[(57)] (76) Ocfentanil
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
[(58)] (77) Ortho-fluoroacryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
[(59)] (78) Ortho-fluorobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
[(60)] (79) Ortho-fluorofentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 2-fluorofentanyl);
(80) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
[(61)] (81) Ortho-fluoroisobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(62)] (82) Ortho-methyl acetylfentanyl
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);
[(63)] (83) Ortho-methyl methoxyacetyl fentanyl
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other
name: 2-methyl methoxyacetyl fentanyl);
(84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(64)] (85) Para-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
[(65)] (86) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propenamide[;]);
[(66)] (87) Para-fluoro furanyl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
(89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
[(67)] (91) Para-methylfentanyl
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other
name: 4-methylfentanyl);
[(68)] (92) PEPAP (1-([-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
[(69)] (93) Phenadoxone;
[(70)] (94) Phenampromide;
[(71)] (95) Phenomorphan;
[(72)] (96) Phenoperidine;
[(73)] (97) Phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl);
[(74)] (98) Piritramide;
[(75)] (99) Proheptazine;
[(76)] (100) Properidine;
[(77)] (101) Propiram;
(102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
[(78)] (103) Racemoramide;
(104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
[(79)] (105) Thenylfentanyl
(N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers,
salts, and salts of isomers;
[(80)] (106) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
[(81)] (107) Thiofuranyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other
names: 2-thiofuranyl fentanyl; thiophene
fentanyl);
[(82)] (108) Tilidine;
[(83)] (109) Trimeperidine; [and]
[(84)] (110) U-47700
(3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)[.];
and
(110) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)."
2. By amending subsection (d) to read:
"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine (AET);
(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
(3) 2,5-dimethoxyamphetamine (2,5-DMA);
(4) 3,4-methylenedioxy amphetamine;
(5) 3,4-methylenedioxymethamphetamine (MDMA);
(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
(11) 3,4,5-trimethoxy amphetamine;
(12) Bufotenine;
(13) 4-methoxyamphetamine (PMA);
(14) Diethyltryptamine;
(15) Dimethyltryptamine;
(16) 4-methyl-2,5-dimethoxy-amphetamine;
(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
(18) Ibogaine;
(19) Lysergic acid diethylamide;
(20) Marijuana;
(21) Parahexyl;
(22) Mescaline;
(23) Peyote;
(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Psilocybin;
(27) Psilocyn;
(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
(29) Ethylamine analog of phencyclidine (PCE);
(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
(31) Thiophene analog of phencyclidine (TPCP; TCP);
(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
(35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers;
(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
(37) Alpha-methyltryptamine (AMT);
(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(39) Salvia divinorum;
(40) Salvinorin A;
(41) Divinorin A;
(42) 5-Methoxy-N,N-Dimethyltryptamine [(5-MeO-DIPT)]
(some trade or other names:
5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);
(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
(60) 4'-chloro-alpha-pyrrolidinovalerophenone,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: 4-chloro-[alpha]-PVP;
4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
[and]
(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
(methoxetamine, MXE)[.];
(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) (Other name: bk-EBDB);
(63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation;
(64) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
(65) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11);
(66) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: ADB-FUBINACA);
(67) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA);
(68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-FUBINACA); and
(69) N-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one)."
3. By amending subsection (f) to read:
"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)amino]ehptanoic acid);
[(1)] (2) Aminorex;
[(2)] (3) Cathinone;
[(3)] (4) 4,4'-dimethylaminorex (common name:
4,4'-DMAR);
(5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
[(4)] (6) Fenethylline;
(7) Mesocarb (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
[(5)] (8) Methcathinone;
(9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
[(6)] (10) 4-methylaminorex;
[(7)] (11) N-ethylamphetamine;
[(8)] (12) N,N-dimethylamphetamine;
[(9)] (13) Substituted cathinones, any compound, except
bupropion or compounds listed under a different schedule, structurally derived
from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,
naphthyl, or thiophene ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) By substitution at the 3-position with an acyclic alkyl substituent; or
(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and
[(10)] (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
(Other names:
para-methoxymethamphetamine; PMMA)."
SECTION 2. Section 329-16, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:
"(f) Immediate precursor. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
(A) Phenylacetone, phenyl-2-propanone (P2P), benzyl methyl ketone, methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine; or
(B) 1-piperidinocyclohexanecarbonitrile (PCC); or
(3) Immediate
precursor to [Fentanyl:] fentanyl:
(A) [4-anilino-N-phenethyl-4-piperidine]
4-anilino-N-phenethylpiperidine (ANPP); or
(B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)."
SECTION 3. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:
"§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.
(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Brexanolone;
(4) Bromazepam;
(5) Butorphanol;
(6) Camazepam;
(7) Carisoprodol;
(8) Chloral betaine;
(9) Chloral hydrate;
(10) Chlordiazepoxide;
(11) Clobazam;
(12) Clonazepam;
(13) Clorazepate;
(14) Clotiazepam;
(15) Cloxazolam;
(16) Daridorexant;
(17) Delorazepam;
(18) Diazepam;
(19) Dichloralphenazone (Midrin);
(20) Estazolam;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Ethyl loflazepate;
(24) Fludiazepam;
(25) Flunitrazepam;
(26) Flurazepam;
(27) Fospropofol (Lusedra);
(28) Halazepam;
(29) Haloxazolam;
(30) Ketazolam;
(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);
(32) Loprazolam;
(33) Lorazepam;
(34) Lormetazepam;
(35) Mebutamate;
(36) Medazepam;
(37) Meprobamate;
(38) Methohexital;
(39) Methylphenobarbital (mephorbarbital);
(40) Midazolam;
(41) Nimetazepam;
(42) Nitrazepam;
(43) Nordiazepam;
(44) Oxazepam;
(45) Oxazolam;
(46) Paraldehyde;
(47) Petrichloral;
(48) Phenobarbital;
(49) Pinazepam;
(50) Prazepam;
(51) Quazepam;
(52) Remimazolam;
(53) Suvorexant;
(54) Temazepam;
(55) Tetrazepam;
(56) Triazolam;
(57) Zaleplon;
(58) Zolpidem; [and]
(59) Zopiclone (Lunesta)[.]; and
(60) Zuranolone.
[(c) Fenfluramine.
Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including its salts, isomers, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible: Fenfluramine.
(d)]
(c) Stimulants. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances having a
stimulant effect on the central nervous system, including its salts, isomers,
and salts of such isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Lorcaserin;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradrol;
(12) Serdexmethylphenidate;
(13) Sibutramine;
(14) Solriamfetol; and
(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
[(e)]
(d) Other substances. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation [which]
that contains any quantity of the following substances, including its
optical isomers and its salts, isomers, and salts of isomers:
(1) Pentazocine; and
(2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
acid[.]).
[(f)]
(e) The department of law
enforcement may except by rule any compound, mixture, or preparation containing
any depressant substance listed in subsection (b) or any stimulant listed in
subsection [(d)] (c) from the application of all or any part of
this chapter if the compound, mixture, or preparation contains one or more
active medicinal ingredients not having a depressant or stimulant effect on the
central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the degree of
danger or probable danger of the substances which have a depressant or
stimulant effect on the central nervous system.
[(g)]
(f) Narcotic drugs. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;
(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane); and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."
SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 5. This Act shall take effect on July 1, 3000.
Report Title:
Uniform Controlled Substances Act; Federal Controlled Substances Act
Description:
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/3000. (HD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1452 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
S.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:
1. By amending subsection (b) to read:
"(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
(6) Allylprodine;
(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(8) Alphameprodine;
(9) Alphamethadol;
(10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(10)] (11) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
[(11)] (12) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(12)] (13) Benzethidine;
[(13)] (14) Benzylfentanyl
(N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and
salts of isomers;
[(14)] (15) Betacetylmethadol;
[(15)] (16) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
[(16)] (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
[(17)] (18) Beta-hydroxythiofentanyl
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
[(18)] (19) Betameprodine;
[(19)] (20) Betamethadol;
[(20)] (21) Beta-methyl fentanyl
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);
[(21)] (22) Beta'-phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl
fentanyl);
[(22)] (23) Betaprodine;
(24) Brorphine 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one;
[(23)] (25) Butyryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
[(24)] (26) Clonitazene;
[(25)] (27) Cyclopropyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
[(26)] (28) Dextromoramide;
[(27)] (29) Diampromide;
[(28)] (30) Diethylthiambutene;
[(29)] (31) Difenoxin;
[(30)] (32) Dimenoxadol;
[(31)] (33) Dimepheptanol;
(34) 2′,5′-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
[(32)] (35) Dimethylthiambutene;
[(33)] (36) Dioxaphetyl butyrate;
[(34)] (37) Dipipanone;
[(35)] (38) Ethylmethylthiambutene;
(39) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene);
[(36)] (40) Etonitazene;
[(37)] (41) Etoxeridine;
[(38)] (42) Fentanyl carbamate (ethyl
(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
[(39)] (43) 4-fluoroisobutyryl fentanyl
[N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: para-fluoroisobutyryl fentanyl);
[(40)] (44) 2'-fluoro ortho-fluorofentanyl
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other
name: 2'-fluoro 2-fluorofentanyl);
[(41)] (45) Furanyl fentanyl
(N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);
(46) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
[(42)] (47) Furethidine;
[(43)] (48) Hydroxypethidine;
(49) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(44)] (50) Ketobemidone;
[(45)] (51) Levomoramide;
[(46)] (52) Levophenacylmorphan;
(53) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(54) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(47)] (55) Methoxyacetyl fentanyl
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(56) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
(57) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(48)] (58) 4'-methyl acetyl fentanyl
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
[(49)] (59) 3-methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
[(50)] (60) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(51)] (61) Morpheridine;
[(52)] (62) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(63) N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine (other name: protonitazene);
(64) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (other name: etonitazepyne);
[(53)] (65) Noracymethadol;
[(54)] (66) Norlevorphanol;
[(55)] (67) Normethadone;
[(56)] (68) Norpipanone;
[(57)] (69) Ocfentanil
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
[(58)] (70) Ortho-fluoroacryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
[(59)] (71) Ortho-fluorobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
(72) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
[(60)] (73) Ortho-fluorofentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);
[(61)] (74) Ortho-fluoroisobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(62)] (75) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide)
(Other name: 2-methyl acetylfentanyl);
[(63)] (76) Ortho-methyl methoxyacetyl fentanyl
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other
name: 2-methyl methoxyacetyl fentanyl);
[(64)] (77) Para-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
[(65)] (78) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide;
[(66)] (79) Para-fluoro furanyl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(80) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(81) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
[(67)] (82) Para-methylfentanyl
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl);
[(68)] (83) PEPAP
(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
[(69)] (84) Phenadoxone;
[(70)] (85) Phenampromide;
[(71)] (86) Phenomorphan;
[(72)] (87) Phenoperidine;
[(73)] (88) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)
(Other name: benzoyl fentanyl);
[(74)] (89) Piritramide;
[(75)] (90) Proheptazine;
[(76)] (91) Properidine;
[(77)] (92) Propiram;
[(78)] (93) Racemoramide;
[(79)] (94) Thenylfentanyl
(N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers,
salts, and salts of isomers;
[(80)] (95) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
[(81)] (96) Thiofuranyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl);
[(82)] (97) Tilidine;
[(83)] (98) Trimeperidine; and
[(84)] (99) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide."
2. By amending subsection (d) to read:
"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine (AET);
(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
(3) 2,5-dimethoxyamphetamine (2,5-DMA);
(4) 3,4-methylenedioxy amphetamine;
(5) 3,4-methylenedioxymethamphetamine (MDMA);
(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
(11) 3,4,5-trimethoxy amphetamine;
(12) Bufotenine;
(13) 4-methoxyamphetamine (PMA);
(14) Diethyltryptamine;
(15) Dimethyltryptamine;
(16) 4-methyl-2,5-dimethoxy-amphetamine;
(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
(18) Ibogaine;
(19) Lysergic acid diethylamide;
(20) Marijuana;
(21) Parahexyl;
(22) Mescaline;
(23) Peyote;
(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Psilocybin;
(27) Psilocyn;
(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
(29) Ethylamine analog of phencyclidine (PCE);
(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
(31) Thiophene analog of phencyclidine (TPCP; TCP);
(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
(35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers;
(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
(37) Alpha-methyltryptamine (AMT);
(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(39) Salvia divinorum;
(40) Salvinorin A;
(41) Divinorin A;
(42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);
(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
(60) 4'-chloro-alpha-pyrrolidinovalerophenone,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-pyrrolidinopentiophenone;
1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [and]
(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
(methoxetamine, MXE)[.];
(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one)(other name: bk-EBDB); and
(63) Zipeprol (1-methoxy-3[-4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation."
3. By amending subsection (f) to read:
"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Amineptine;
[(1)] (2) Aminorex;
[(2)] (3) Cathinone;
[(3)] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);
[(4)] (5) Fenethylline;
(6) Mesocarb (chemical name: N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
[(5)] (7) Methcathinone;
(8) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
[(6)] (9) 4-methylaminorex;
[(7)] (10) N-ethylamphetamine;
[(8)] (11) N,N-dimethylamphetamine;
[(9)] (12) Substituted cathinones, any compound, except
bupropion or compounds listed under a different schedule, structurally derived
from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,
naphthyl, or thiophene ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) By substitution at the 3-position with an acyclic alkyl substituent; or
(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and
[(10)] (13) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
(Other names: para-methoxymethamphetamine; PMMA)."
SECTION 2. Section 329-16, Hawaii Revised Statutes, is amended by amending subsection (f) to read as follows:
"(f) Immediate precursor. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
(A) Phenylacetone, phenyl-2-propanone(P2P), benzyl methyl ketone, methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine; or
(B) 1-piperidinocyclohexanecarbonitrile(PCC); or
(3) Immediate precursor to Fentanyl:
(A) [4-anilino-N-phenethyl-4-piperidine]
4-anilino-N-phenethylpiperidine (ANPP); or
(B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)."
SECTION 3. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:
"§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.
(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Brexanolone;
(4) Bromazepam;
(5) Butorphanol;
(6) Camazepam;
(7) Carisoprodol;
(8) Chloral betaine;
(9) Chloral hydrate;
(10) Chlordiazepoxide;
(11) Clobazam;
(12) Clonazepam;
(13) Clorazepate;
(14) Clotiazepam;
(15) Cloxazolam;
(16) Daridorexant;
(17) Delorazepam;
(18) Diazepam;
(19) Dichloralphenazone (Midrin);
(20) Estazolam;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Ethyl loflazepate;
(24) Fludiazepam;
(25) Flunitrazepam;
(26) Flurazepam;
(27) Fospropofol (Lusedra);
(28) Halazepam;
(29) Haloxazolam;
(30) Ketazolam;
(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);
(32) Loprazolam;
(33) Lorazepam;
(34) Lormetazepam;
(35) Mebutamate;
(36) Medazepam;
(37) Meprobamate;
(38) Methohexital;
(39) Methylphenobarbital (mephorbarbital);
(40) Midazolam;
(41) Nimetazepam;
(42) Nitrazepam;
(43) Nordiazepam;
(44) Oxazepam;
(45) Oxazolam;
(46) Paraldehyde;
(47) Petrichloral;
(48) Phenobarbital;
(49) Pinazepam;
(50) Prazepam;
(51) Quazepam;
(52) Remimazolam;
(53) Suvorexant;
(54) Temazepam;
(55) Tetrazepam;
(56) Triazolam;
(57) Zaleplon;
(58) Zolpidem; [and]
(59) Zopiclone (Lunesta)[.]; and
(60) Zuranolone.
[(c) Fenfluramine.
Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including its salts, isomers, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible: Fenfluramine.
(d)]
(c) Stimulants. Unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers, and salts of such isomers whenever the existence
of such salts, isomers, and salts of isomers is possible within the specific
chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Lorcaserin;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradrol;
(12) Serdexmethylphenidate;
(13) Sibutramine;
(14) Solriamfetol; and
(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
[(e)]
(d) Other substances. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances, including its optical
isomers and its salts, isomers, and salts of isomers:
(1) Pentazocine; and
(2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid.
[(f)]
(e) The department of law
enforcement may except by rule any compound, mixture, or preparation containing
any depressant substance listed in subsection (b) or any stimulant listed in
subsection [(d)] (c) from the application of all or any part of
this chapter if the compound, mixture, or preparation contains one or more
active medicinal ingredients not having a depressant or stimulant effect on the
central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the degree of
danger or probable danger of the substances which have a depressant or
stimulant effect on the central nervous system.
[(g)]
(f) Narcotic drugs. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;
(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane); and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."
SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 5. This Act shall take effect on July 1, 2077.
Report Title:
Uniform Controlled Substances Act
Description:
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS. Effective 7/1/2077. (SD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
THE SENATE |
S.B. NO. |
1452 |
|
THIRTY-THIRD LEGISLATURE, 2025 |
|
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:
1. By amending subsection (b) to read:
"(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
(4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
(6) Allylprodine;
(7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(8) Alphameprodine;
(9) Alphamethadol;
(10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(10)] (11) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
[(11)] (12) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(12)] (13) Benzethidine;
[(13)] (14) Benzylfentanyl
(N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and
salts of isomers;
[(14)] (15) Betacetylmethadol;
[(15)] (16) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
[(16)] (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
[(17)] (18) Beta-hydroxythiofentanyl
(N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
[(18)] (19) Betameprodine;
[(19)] (20) Betamethadol;
[(20)] (21) Beta-methyl fentanyl
(N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl);
[(21)] (22) Beta'-phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl
fentanyl);
[(22)] (23) Betaprodine;
(24) Brorphine 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one;
[(23)] (25) Butyryl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
[(24)] (26) Clonitazene;
[(25)] (27) Cyclopropyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
[(26)] (28) Dextromoramide;
[(27)] (29) Diampromide;
[(28)] (30) Diethylthiambutene;
[(29)] (31) Difenoxin;
[(30)] (32) Dimenoxadol;
[(31)] (33) Dimepheptanol;
(34) 2′,5′-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
[(32)] (35) Dimethylthiambutene;
[(33)] (36) Dioxaphetyl butyrate;
[(34)] (37) Dipipanone;
[(35)] (38) Ethylmethylthiambutene;
(39) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene);
[(36)] (40) Etonitazene;
[(37)] (41) Etoxeridine;
[(38)] (42) Fentanyl carbamate (ethyl
(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
[(39)] (43) 4-fluoroisobutyryl fentanyl
[N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: para-fluoroisobutyryl fentanyl);
[(40)] (44) 2'-fluoro ortho-fluorofentanyl
(N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other
name: 2'-fluoro 2-fluorofentanyl);
[(41)] (45) Furanyl fentanyl
(N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide);
(46) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
[(42)] (47) Furethidine;
[(43)] (48) Hydroxypethidine;
(49) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
[(44)] (50) Ketobemidone;
[(45)] (51) Levomoramide;
[(46)] (52) Levophenacylmorphan;
(53) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
(54) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(47)] (55) Methoxyacetyl fentanyl
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(56) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
(57) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
[(48)] (58) 4'-methyl acetyl fentanyl
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
[(49)] (59) 3-methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
[(50)] (60) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
[(51)] (61) Morpheridine;
[(52)] (62) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(63) N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine (other name: protonitazene);
(64) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (other name: etonitazepyne);
[(53)] (65) Noracymethadol;
[(54)] (66) Norlevorphanol;
[(55)] (67) Normethadone;
[(56)] (68) Norpipanone;
[(57)] (69) Ocfentanil
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
[(58)] (70) Ortho-fluoroacryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
[(59)] (71) Ortho-fluorobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl);
(72) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
[(60)] (73) Ortho-fluorofentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);
[(61)] (74) Ortho-fluoroisobutyryl fentanyl
(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
[(62)] (75) Ortho-methyl acetylfentanyl
(N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl);
[(63)] (76) Ortho-methyl methoxyacetyl fentanyl
(2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other
name: 2-methyl methoxyacetyl fentanyl);
[(64)] (77) Para-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
[(65)] (78) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide;
[(66)] (79) Para-fluoro furanyl fentanyl
(N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(80) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
(81) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
[(67)] (82) Para-methylfentanyl
(N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl);
[(68)] (83) PEPAP
(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
[(69)] (84) Phenadoxone;
[(70)] (85) Phenampromide;
[(71)] (86) Phenomorphan;
[(72)] (87) Phenoperidine;
[(73)] (88) Phenyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl);
[(74)] (89) Piritramide;
[(75)] (90) Proheptazine;
[(76)] (91) Properidine;
[(77)] (92) Propiram;
[(78)] (93) Racemoramide;
[(79)] (94) Thenylfentanyl
(N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers,
salts, and salts of isomers;
[(80)] (95) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
[(81)] (96) Thiofuranyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl);
[(82)] (97) Tilidine;
[(83)] (98) Trimeperidine; and
[(84)] (99) U-47700
(3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide."
2. By amending subsection (d) to read:
"(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine (AET);
(2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
(3) 2,5-dimethoxyamphetamine (2,5-DMA);
(4) 3,4-methylenedioxy amphetamine;
(5) 3,4-methylenedioxymethamphetamine (MDMA);
(6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
(7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
(9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
(10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
(11) 3,4,5-trimethoxy amphetamine;
(12) Bufotenine;
(13) 4-methoxyamphetamine (PMA);
(14) Diethyltryptamine;
(15) Dimethyltryptamine;
(16) 4-methyl-2,5-dimethoxy-amphetamine;
(17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
(18) Ibogaine;
(19) Lysergic acid diethylamide;
(20) Marijuana;
(21) Parahexyl;
(22) Mescaline;
(23) Peyote;
(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Psilocybin;
(27) Psilocyn;
(28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
(29) Ethylamine analog of phencyclidine (PCE);
(30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
(31) Thiophene analog of phencyclidine (TPCP; TCP);
(32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;
(33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;
(34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;
(35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers;
(36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;
(37) Alpha-methyltryptamine (AMT);
(38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(39) Salvia divinorum;
(40) Salvinorin A;
(41) Divinorin A;
(42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT);
(43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
(52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
(53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
(54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
(55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);
(56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
(57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);
(58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
(59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
(60) 4'-chloro-alpha-pyrrolidinovalerophenone,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-pyrrolidinopentiophenone;
1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [and]
(61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
(methoxetamine, MXE)[.];
(62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one)(other name: bk-EBDB); and
(63) Zipeprol (1-methoxy-3[-4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation."
3. By amending subsection (f) to read:
"(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Amineptine;
[(1)] (2) Aminorex;
[(2)] (3) Cathinone;
[(3)] (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);
[(4)] (5) Fenethylline;
(6) Mesocarb (chemical name: N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
[(5)] (7) Methcathinone;
(8) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);
[(6)] (9) 4-methylaminorex;
[(7)] (10) N-ethylamphetamine;
[(8)] (11) N,N-dimethylamphetamine;
[(9)] (12) Substituted cathinones, any compound, except
bupropion or compounds listed under a different schedule, structurally derived
from 2-aminopropan-1-one by substitution at the 1-position with either phenyl,
naphthyl, or thiophene ring systems, whether or not the compound is further
modified in any of the following ways:
(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) By substitution at the 3-position with an acyclic alkyl substituent; or
(C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and
[(10)] (13) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
(Other names: para-methoxymethamphetamine; PMMA)."
SECTION 2. Section 329-20, Hawaii Revised Statutes, is amended to read as follows:
"§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.
(b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Brexanolone;
(4) Bromazepam;
(5) Butorphanol;
(6) Camazepam;
(7) Carisoprodol;
(8) Chloral betaine;
(9) Chloral hydrate;
(10) Chlordiazepoxide;
(11) Clobazam;
(12) Clonazepam;
(13) Clorazepate;
(14) Clotiazepam;
(15) Cloxazolam;
(16) Daridorexant;
(17) Delorazepam;
(18) Diazepam;
(19) Dichloralphenazone (Midrin);
(20) Estazolam;
(21) Ethchlorvynol;
(22) Ethinamate;
(23) Ethyl loflazepate;
(24) Fludiazepam;
(25) Flunitrazepam;
(26) Flurazepam;
(27) Fospropofol (Lusedra);
(28) Halazepam;
(29) Haloxazolam;
(30) Ketazolam;
(31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide);
(32) Loprazolam;
(33) Lorazepam;
(34) Lormetazepam;
(35) Mebutamate;
(36) Medazepam;
(37) Meprobamate;
(38) Methohexital;
(39) Methylphenobarbital (mephorbarbital);
(40) Midazolam;
(41) Nimetazepam;
(42) Nitrazepam;
(43) Nordiazepam;
(44) Oxazepam;
(45) Oxazolam;
(46) Paraldehyde;
(47) Petrichloral;
(48) Phenobarbital;
(49) Pinazepam;
(50) Prazepam;
(51) Quazepam;
(52) Remimazolam;
(53) Suvorexant;
(54) Temazepam;
(55) Tetrazepam;
(56) Triazolam;
(57) Zaleplon;
(58) Zolpidem; [and]
(59) Zopiclone (Lunesta)[.]and
(60) Zuranolone.
[(c) Fenfluramine.
Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including its salts, isomers, and salts
of isomers, whenever the existence of such salts, isomers, and salts of isomers
is possible: Fenfluramine.
(d)]
(c) Stimulants. Unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers, and salts of such isomers whenever the existence
of such salts, isomers, and salts of isomers is possible within the specific
chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Lorcaserin;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradrol;
(12) Serdexmethylphenidate;
(13) Sibutramine;
(14) Solriamfetol; and
(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).
[(e)]
(d) Other substances. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances, including its optical
isomers and its salts, isomers, and salts of isomers:
(1) Pentazocine; and
(2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid.
[(f)]
(e) The department of law
enforcement may except by rule any compound, mixture, or preparation containing
any depressant substance listed in subsection (b) or any stimulant listed in
subsection [(d)] (c) from the application of all or any part of
this chapter if the compound, mixture, or preparation contains one or more
active medicinal ingredients not having a depressant or stimulant effect on the
central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the degree of
danger or probable danger of the substances which have a depressant or
stimulant effect on the central nervous system.
[(g)]
(f) Narcotic drugs. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit;
(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane); and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)."
SECTION 3. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 4. This Act shall take effect upon its approval.
|
INTRODUCED BY: |
_____________________________ |
|
|
BY REQUEST |
Report Title:
Uniform Controlled Substances Act
Description:
Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS.
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
|
Date
|
Status
|
|---|---|
| May 29, 2025 | Act 107, on 05/29/2025 (Gov. Msg. No. 1207). |
| May 29, 2025 | Act 107, 05/29/2025 (Gov. Msg. No. 1207). |
| May 2, 2025 | Enrolled to Governor. |
| May 2, 2025 | Received notice of passage on Final Reading in House (Hse. Com. No. 821). |
| May 1, 2025 | Received notice of Final Reading (Sen. Com. No. 888). |
| Apr 30, 2025 | Passed Final Reading as amended in CD 1 with none voting aye with reservations; none voting no (0) and Representative(s) Cochran, Pierick excused (2). |
| Apr 30, 2025 | Passed Final Reading, as amended (CD 1). Ayes, 25; Aye(s) with reservations: none . 0 No(es): none. 0 Excused: none. |
| Apr 24, 2025 | Forty-eight (48) hours notice Wednesday, 04-30-25. |
| Apr 24, 2025 | Reported from Conference Committee (Conf Com. Rep. No. 10) as amended in (CD 1). |
| Apr 24, 2025 | 48 Hrs. Notice (as amended CD 1) 04-30-25. |
| Apr 24, 2025 | Reported from Conference Committee as amended CD 1 (Conf. Com. Rep. No. 10). |
| Apr 17, 2025 | The Conference Committee recommends that the measure be Passed, with Amendments. The votes were as follows: 3 Ayes: Representative(s) Takayama, Poepoe, Alcos; Ayes with reservations: none; 0 Noes: none; and 0 Excused: none. |
| Apr 17, 2025 | The Conference committee recommends that the measure be PASSED, WITH AMENDMENTS. The votes of the Senate Conference Managers were as follows: 3 Aye(s): Senator(s) Elefante, Gabbard, Fukunaga; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) DeCorte. |
| Apr 16, 2025 | Conference committee meeting scheduled for 04-17-25 3:30PM; Conference Room 016. |
| Apr 15, 2025 | Received notice of Senate conferees (Sen. Com. No. 789). |
| Apr 15, 2025 | Senate Conferees Appointed: Elefante Chair; Gabbard Co-Chair; Fukunaga, DeCorte. |
| Apr 15, 2025 | Received notice of appointment of House conferees (Hse. Com. No. 731). |
| Apr 14, 2025 | House Conferees Appointed: Takayama, Poepoe Co-Chairs; Alcos. |
| Apr 8, 2025 | Received notice of disagreement (Sen. Com. No. 774). |
| Apr 8, 2025 | Senate disagrees with House amendments. |
| Apr 8, 2025 | Received from House (Hse. Com. No. 613). |
| Apr 4, 2025 | Passed Third Reading as amended in HD 2 with none voting aye with reservations; Representative(s) Pierick voting no (1) and Representative(s) Cochran excused (1). Transmitted to Senate. |
| Apr 2, 2025 | Forty-eight (48) hours notice Friday, 04-04-25. |
| Apr 2, 2025 | Reported from JHA (Stand. Com. Rep. No. 1783) as amended in HD 2, recommending passage on Third Reading. |
| Mar 25, 2025 | The committee on JHA recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 10 Ayes: Representative(s) Tarnas, Poepoe, Belatti, Cochran, Hashem, Perruso, Takayama, Todd, Garcia, Shimizu; Ayes with reservations: none; 0 Noes: none; and 1 Excused: Representative(s) Kahaloa. |
| Mar 21, 2025 | Bill scheduled to be heard by JHA on Tuesday, 03-25-25 2:00PM in House conference room 325 VIA VIDEOCONFERENCE. |
| Mar 21, 2025 | Passed Second Reading as amended in HD 1 and referred to the committee(s) on JHA with none voting aye with reservations; Representative(s) Pierick voting no (1) and Representative(s) Cochran, Garrett, Kapela, Kitagawa, Ward excused (5). |
| Mar 21, 2025 | Reported from HLT (Stand. Com. Rep. No. 1422) as amended in HD 1, recommending passage on Second Reading and referral to JHA. |
| Mar 19, 2025 | The committee on HLT recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 9 Ayes: Representative(s) Takayama, Keohokapu-Lee Loy, Amato, Chun, Marten, Olds, Takenouchi, Alcos, Garcia; Ayes with reservations: none; 0 Noes: none; and 0 Excused: none. |
| Mar 14, 2025 | Bill scheduled to be heard by HLT on Wednesday, 03-19-25 9:05AM in House conference room 329 VIA VIDEOCONFERENCE. |
| Mar 6, 2025 | Referred to HLT, JHA, referral sheet 19 |
| Mar 6, 2025 | Pass First Reading |
| Mar 4, 2025 | Received from Senate (Sen. Com. No. 343) in amended form (SD 1). |
| Mar 4, 2025 | Report adopted; Passed Third Reading. Ayes, 25; Aye(s) with reservations: none . Noes, 0 (none). Excused, 0 (none). Transmitted to House. |
| Feb 28, 2025 | One Day Notice 03-04-25. |
| Feb 28, 2025 | Reported from JDC (Stand. Com. Rep. No. 968) with recommendation of passage on Third Reading. |
| Feb 26, 2025 | The committee(s) on JDC recommend(s) that the measure be PASSED, UNAMENDED. The votes in JDC were as follows: 4 Aye(s): Senator(s) Rhoads, Gabbard, Chang, San Buenaventura; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Awa. |
| Feb 21, 2025 | The committee(s) on JDC will hold a public decision making on 02-26-25 9:40AM; Conference Room 016 & Videoconference. |
| Feb 12, 2025 | Report adopted; Passed Second Reading, as amended (SD 1) and referred to JDC. |
| Feb 12, 2025 | Reported from PSM (Stand. Com. Rep. No. 276) with recommendation of passage on Second Reading, as amended (SD 1) and referral to JDC. |
| Feb 7, 2025 | The committee(s) on PSM recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in PSM were as follows: 4 Aye(s): Senator(s) Elefante, Wakai, Fukunaga, Rhoads; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) DeCorte. |
| Feb 3, 2025 | The committee(s) on PSM deferred the measure until 02-07-25 3:15PM; CR 225. |
| Jan 30, 2025 | The committee(s) on PSM has scheduled a public hearing on 02-03-25 3:15PM; Conference Room 225 & Videoconference. |
| Jan 27, 2025 | Referred to PSM, JDC. |
| Jan 23, 2025 | Introduced and passed First Reading. |
| Jan 21, 2025 | Pending Introduction. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 30, 2025 | Final Reading | House Floor |
Passed |
|
| Apr 30, 2025 | Final Reading | Senate Floor |
Passed |
|
| Apr 4, 2025 | Third Reading | House Floor |
Passed |
|
| Mar 25, 2025 | The committee on JHA recommend that the measure be PASSED, WITH AMENDMENTS | House Standing Committee on Judiciary & Hawaiian Affairs |
Passed |
|
| Mar 19, 2025 | The committee on HLT recommend that the measure be PASSED, WITH AMENDMENTS | House Standing Committee on Health |
Passed |
|
| Mar 4, 2025 | Third Reading | Senate Floor |
Passed |
|
| Feb 26, 2025 | The committee(s) on JDC recommend(s) that the measure be PASSED, UNAMENDED | Senate Standing Committee on Judiciary |
Passed |
|
| Feb 7, 2025 | The committee(s) on PSM recommend(s) that the measure be PASSED, WITH AMENDMENTS | Senate Standing Committee on Public Safety and Military Affairs |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| County of Honolulu | ** Support | |
| Department of Law Enforcement | ** Support | |
| Department of Law Enforcement and Department of the Prosecuting Attorney for the City | ** Support | |
| Department of the Prosecuting Attorney, City and County of Honolulu | *** Support | Feb 3, 2025 |
CONFERENCE COMMITTEE REP. NO. 10
Honolulu, Hawaii
, 2025
RE: S.B. No. 1452
S.D. 1
H.D. 2
C.D. 1
Honorable Ronald D. Kouchi
President of the Senate
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Honorable Nadine K. Nakamura
Speaker, House of Representatives
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Sir and Madam:
Your Committee on Conference on the disagreeing vote of the Senate to the amendments proposed by the House of Representatives in S.B. No. 1452, S.D. 1, H.D. 2, entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT,"
having met, and after full and free discussion, has agreed to recommend and does recommend to the respective Houses the final passage of this bill in an amended form.
The purpose of this measure is to update chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, Hawaii Revised Statutes.
Your Committee on Conference finds that it is critical to public safety, effective law enforcement, and proper compliance with state law that the State's controlled substances schedules are consistent with the current federal regulations. Your Committee on Conference further finds that this measure will help prevent confusion among law enforcement agencies, healthcare providers, and the public regarding the status of different controlled substances.
Your Committee on Conference has amended this measure by changing its effective date to July 1, 2025.
As affirmed by the record of votes of the managers of your Committee on Conference that is attached to this report, your Committee on Conference is in accord with the intent and purpose of S.B. No. 1452, S.D. 1, H.D. 2, as amended herein, and recommends that it pass Final Reading in the form attached hereto as S.B. No. 1452, S.D. 1, H.D. 2, C.D. 1.
Respectfully submitted on behalf of the managers:
|
ON THE PART OF THE HOUSE |
|
ON THE PART OF THE SENATE |
|
____________________________ GREGG TAKAYAMA Co-Chair |
|
____________________________ BRANDON J.C. ELEFANTE Chair |
|
____________________________ MAHINA POEPOE Co-Chair |
|
____________________________ MIKE GABBARD Co-Chair |
|
|
|
|
|
|
|
|
STAND. COM. REP. NO. 1783
Honolulu, Hawaii
, 2025
RE: S.B. No. 1452
S.D. 1
H.D. 2
Honorable Nadine K. Nakamura
Speaker, House of Representatives
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Madame:
Your Committee on Judiciary & Hawaiian Affairs, to which was referred S.B. No. 1452, S.D. 1, H.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT,"
begs leave to report as follows:
Your Committee received testimony in support of this measure from the Department of Law Enforcement.
Your Committee finds that this measure is necessary to make permanent the temporary designation of new controlled substances by the Department of Law Enforcement. Your Committee further finds that the Department of Law Enforcement's temporary designation of the new controlled substances will be nullified if this Legislature does not make the designations permanent.
Your Committee has amended this measure by making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.
As affirmed by the record of votes of the members of your Committee on Judiciary & Hawaiian Affairs that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1452, S.D. 1, H.D. 1, as amended herein, and recommends that it pass Third Reading in the form attached hereto as S.B. No. 1452, S.D. 1, H.D. 2.
Respectfully submitted on behalf of the members of the Committee on Judiciary & Hawaiian Affairs,
|
|
|
____________________________ DAVID A. TARNAS, Chair |
|
|
|
|
STAND. COM. REP. NO. 1422
Honolulu, Hawaii
, 2025
RE: S.B. No. 1452
S.D. 1
H.D. 1
Honorable Nadine K. Nakamura
Speaker, House of Representatives
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Madame:
Your Committee on Health, to which was referred S.B. No. 1452, S.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT,"
begs leave to report as follows:
The purpose of this measure is to update the State's Uniform Controlled Substance Act to make it consistent with amendments to the federal Controlled Substances Act.
Your Committee received testimony in support of this measure from the Department of Law Enforcement.
Your Committee finds that this measure fulfills the Department of Law Enforcement's statutory obligation to recommend to the Legislature any changes to state law that would correspond to changes in federal law regarding the scheduling of controlled substances.
Your Committee has amended this measure by:
(1) Making additional conforming amendments to conform state law with the federal Controlled Substances Act;
(2) Changing the effective date to July 1, 3000, to encourage further discussion; and
(3) Making technical, nonsubstantive amendments for the purposes of clarity, consistency, and style.
As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1452, S.D. 1, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 1452, S.D. 1, H.D. 1, and be referred to your Committee on Judiciary & Hawaiian Affairs.
Respectfully submitted on behalf of the members of the Committee on Health,
|
|
|
____________________________ GREGG TAKAYAMA, Chair |
|
|
|
|
STAND. COM. REP. NO. 968
Honolulu, Hawaii
RE: S.B. No. 1452
S.D. 1
Honorable Ronald D. Kouchi
President of the Senate
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Sir:
Your Committee on Judiciary, to which was referred S.B. No. 1452, S.D. 1, entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT,"
begs leave to report as follows:
The purpose and intent of this measure is to update the Uniform Controlled Substances Act to be consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, Hawaii Revised Statutes.
Your Committee did not receive any testimony on this measure.
Your Committee finds that evolution in the illicit drug market necessitates frequent updates to controlled substance schedules. The accuracy of these schedules is critical to law enforcement, public safety, and compliance with national drug control standards. Alignment between state and federal standards also facilitates simpler, more effective compliance and enforcement. This measure will update the State's Uniform Controlled Substances Act to conform with recent updates to its federal counterpart.
As affirmed by the record of votes of the members of your Committee on Judiciary that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1452, S.D. 1, and recommends that it pass Third Reading.
Respectfully submitted on behalf of the members of the Committee on Judiciary,
|
|
|
________________________________ KARL RHOADS, Chair |
|
|
|
|
STAND. COM. REP. NO. 276
Honolulu, Hawaii
RE: S.B. No. 1452
S.D. 1
Honorable Ronald D. Kouchi
President of the Senate
Thirty-Third State Legislature
Regular Session of 2025
State of Hawaii
Sir:
Your Committee on Public Safety and Military Affairs, to which was referred S.B. No. 1452 entitled:
"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT,"
begs leave to report as follows:
The purpose and intent of this measure is to update chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, Hawaii Revised Statutes.
Your Committee received testimony in support of this measure from the Department of Law Enforcement and Department of the Prosecuting Attorney for the City and County of Honolulu.
Your Committee finds that keeping the State's controlled substances schedules current with federal regulations is crucial for effective law enforcement, ensuring public safety, and maintaining compliance with national drug control standards.
Your Committee further finds that the alignment of state and federal controlled substances regulations helps prevent confusion among law enforcement agencies, healthcare providers, and the public regarding the legal status of various substances. It also assures that the State's law enforcement can effectively coordinate with federal agencies in addressing drug-related crimes and maintaining public safety.
Your Committee has amended this measure by:
(1) Correcting the name of a drug from 4‑anilino‑N‑phenethyl-4piperidine to 4‑anilino‑N‑phenethylpiperdine in the list of schedule II controlled substances;
(2) Inserting an effective date of July 1, 2077, to encourage further discussion; and
(3) Making technical, nonsubstantive amendments for the purposes of clarity and consistency.
As affirmed by the record of votes of the members of your Committee on Public Safety and Military Affairs that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1452, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 1452, S.D. 1, and be referred to your Committee on Judiciary.
Respectfully submitted on behalf of the members of the Committee on Public Safety and Military Affairs,
|
|
|
________________________________ BRANDON J.C. ELEFANTE, Chair |
|
|
|
|
|
Date
|
Testimony PDF
|
|---|---|
| Mar 25, 2025 | SB1452_HD1_TESTIMONY_JHA_03-25-25_.PDF |
| Mar 19, 2025 | SB1452_SD1_TESTIMONY_HLT_03-19-25_.PDF |
| Feb 3, 2025 | SB1452_TESTIMONY_PSM_02-03-25_.PDF |
Discussed in Hearing
3MIN
Conference Committee
1MIN
House Standing Committee on Judiciary & Hawaiian Affairs
5SEC
House Standing Committee on Health
5SEC
House Standing Committee on Human Services & Homelessness
Bill Author
Bill Co-Author(s):